Division of Hematology/Oncology

Research & Clinical Trials

Research & Clinical Trials

Pioneering New Treatments for Cancer and Blood Disorders

Penn Hematology/Oncology investigators continue to publish high profile and important findings in diverse fields, ranging from the most fundamental cellular investigations, to the most leading edge translational and clinical research.

Patients receiving treatment at Penn Medicine for cancer and blood disorders are right next door to the research centers where breakthroughs are being discovered every day. They are being treated by experts in hematology and medical oncology care and research who are working relentlessly to find new ways to prevent, detect and treat these diseases.

Research is at the core of what Penn Medicine is about, and it is a key component to finding new, effective treatments and prevention programs for cancer and hematologic disorders.

Clinical Trials for Patients

Today, more and more people are surviving cancer. It is because of clinical trials, many of which are conducted at Penn Medicine that patients are benefiting from breakthrough therapies and treatments.

Penn's Abramson Cancer Center, an NCI-designated comprehensive cancer center, oversees one of the largest clinical trial programs in the country, with more than 200 trials available at any one time.

Phase 1 and 2 clinical trials for cancer are part of the Developmental Therapeutics Program and the Clinical Investigations Research Program at the Abramson Cancer Center.

These new advances in cancer treatment are occurring every day, giving patients hope that even greater discoveries lie ahead. Through clinical trials:

  • Diagnosing cancer has become more precise.
  • Radiation and surgical techniques have advanced.
  • Medications are more successful.
  • Combinations of medical, surgical and radiation therapy are improving treatment effectiveness and enhancing outcomes.
  • Strategies to address the late effects of cancer and its treatment are improving quality of life.

Learn more about the clinical trials at Penn Medicine

For Medical Professionals

Penn's Division of Hematology/Oncology in the Department of Medicine provides comprehensive hematology and medical oncology services, research and training. The division, with its colleagues in other medical specialties, is an integral part of Penn's Abramson Cancer Center, an NCI-designated cancer center. Division faculty is committed to the integration of leading edge research with highest quality and personalized care for our patients.

Services

The division of hematology/oncology offers:

  • Benign and malignant hematology
  • Solid tumor oncology
  • Autologous and Allogeneic stem cell transplants
  • New treatments including molecularly targeted therapies, immunotherapy treatments, vaccine studies made available through innovative clinical trials

The division and the Abramson Cancer Center at Penn have made significant commitment and investment to enhance clinical research and patient comfort and support.

Penn Medicine provides a full breadth of clinical and support services to patients and family members through a variety of multidisciplinary clinical programs focused on specific types of cancer. Members of the division are all subspecialists focusing exclusively on a specific malignancy or blood disorder.

Basic, translational and clinical research in hematology and medical oncology is focused on understanding the biology and causes of cancer and blood disorders and on expediting the transfer of scientific advances from the laboratory bench to patients.

The focus of basic scientists in the division is in the following areas:

  • Platelet biology
  • Hematopoiesis
  • Cancer biology
  • Cancer immunobiology
  • Cancer stem cells
  • HIV/Host blood center interactions

Clinical and translational research is a major focus for faculty in the division of hematology/oncology. Our research encompasses a highly integrated program involving physicians and scientists across the disease spectrum with particular focus in the areas of hematological malignancies, lung cancer, melanoma, head and neck cancer, GU and GI cancers.

Specialized resources include:

Contact

For more information regarding available clinical trials, please contact the principal investigator of each study or Amy Kramer, RN, MPA, administrative director for the phase I program, or Kimberly Craig, Esq., BSN, RN, administrative director of the clinical research unit.